Link Pharma Chem's Q3 Financial Results Decline
Link Pharma Chem, a microcap company in the chemicals industry, reported a decline in net sales, standalone net profit, and operating profit for the quarter ended September 2023. The company's operating profit margin has also fallen, indicating a negative trend. Additionally, the company's net sales and operating cash flow have been consistently decreasing, while the profit after tax and earnings per share have also seen a decline. This may raise concerns for investors.
Link Pharma Chem, a microcap company in the chemicals industry, recently announced its financial results for the quarter ended September 2023. The company's stock has been given a 'Strong Sell' call by MarketsMOJO.
According to the quarterly analysis, there has been a decline in net sales by 23.22% compared to the previous quarter, and a decrease in standalone net profit by 24.39%. The operating profit (PBDIT) excluding other income has also seen a decline of 7.29%. However, there has been a slight improvement in the interest expenses, with a decrease of 4.35%.
The operating profit margin (excluding other income) has fallen from the previous quarter, indicating a negative trend for the company. This is in line with the overall very negative financial performance of Link Pharma Chem for the quarter ended September 2023. This trend has remained consistent for the past three months.
The company's net sales for the quarter have fallen by 30.9% compared to the average net sales of the previous four quarters. Additionally, the operating cash flow has been consistently decreasing over the past three years, indicating a decline in the company's cash revenues from business operations.
The profit after tax (PAT) for the quarter has also seen a decline, with the lowest at Rs -1.02 crore. This trend has been consistent for the past five quarters. The earnings per share (EPS) for the quarter have also decreased, with the lowest at Rs -2.30. This indicates a declining profitability for the company and lower earnings for shareholders.
In summary, the financial results for the quarter ended September 2023 have not been favorable for Link Pharma Chem. The company has seen a decline in net sales, operating cash flow, and profitability, which may be a cause for concern for investors.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
